FEDERAL COURT OF AUSTRALIA
Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 3) [2020] FCA 222
File numbers: NSD 121 of 2012
NSD 837 of 2015Judge: YATES J Date of judgment: 28 February 2020 Catchwords: PRACTICE AND PROCEDURE – enforcement of undertakings as to damages - leave to amend pleadings to withdraw admissions – factors relevant to the exercise of discretion – leave granted Legislation: Federal Court Rules 2011 (Cth) r 26.11
National Health Act 1953 (Cth)Cases cited: Celestino v Celestino [1990] FCA 299
Centrestate Exports Pty Ltd v Amarantos Shipping Co Ltd [2005] SASC 158
Cropper v Smith (1884) 26 Ch D 700
Jeans v Commonwealth Bank of Australia [2003] FCAFC 309; 204 ALR 327
Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2019] FCA 230
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2018] FCA 1556
Date of hearing: 11 and 17 September 2019 Registry: New South Wales Division: General Division National Practice Area: Intellectual Property Sub-area: Patents and associated Statutes Category: Catchwords Number of paragraphs: 66 Counsel for the Applicants/Appellants: Mr S M Nixon SC and Mr J J Hutton Solicitor for the Applicants/Appellants: Jones Day Counsel for the Respondents: Mr S G Habib SC and Mr A R Lang Solicitor for the Respondents: Wrays Lawyers ORDERS
NSD 121 of 2012
BETWEEN: OTSUKA PHARMACEUTICAL CO., LTD
First Applicant/First Appellant
BRISTOL-MYERS SQUIBB COMPANY
Second Applicant/Second Appellant
AND: GENERIC HEALTH PTY LTD (ACN 110 617 859)
First Respondent
COMMONWEALTH OF AUSTRALIA
Other
JUDGE:
YATES J
DATE OF ORDER:
28 FEBRUARY 2020
THE COURT ORDERS THAT:
1.Leave be granted to Otsuka/BMS to withdraw paras 28, 29, 30 and 31(a) of the Response to Statement of Particulars of Claim for Damages filed in Generic Health’s enforcement proceedings, and to file an amended Response to Statement of Particulars of Claim for Damages in the form annexed to their interlocutory application dated 17 April 2019.
2.Otsuka/BMS pay Generic Health’s costs thrown away by reason of the amendments sought.
3.Otsuka/BMS pay the costs of the application to amend.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
ORDERS
NSD 837 of 2015 BETWEEN: OTSUKA PHARMACEUTICAL CO., LTD
First Applicant/First Appellant
BRISTOL-MYERS SQUIBB COMPANY
Second Applicant/Second Appellant
AND: GENERIC HEALTH PTY LTD (ACN 110 617 859)
First Respondent
COMMONWEALTH OF AUSTRALIA
Other
JUDGE:
YATES J
DATE OF ORDER:
28 FEBRUARY 2020
THE COURT ORDERS THAT:
1.Leave be granted to Otsuka/BMS to withdraw paras 30, 31, 32 and 33(a) of the Response to Statement of Particulars of Claim for Damages filed in Generic Health’s enforcement proceedings, and to file an amended Response to Statement of Particulars of Claim for Damages in the form annexed to their amended interlocutory application dated 17 September 2019.
2.Otsuka/BMS pay Generic Health’s costs thrown away by reason of the amendments sought.
3.Otsuka/BMS pay the costs of the application to amend.
Note: Entry of…
Keep reading for free
Create a free CaseChat account to read Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2020] FCA 222
- Decision Date
CaseChat Overview and Summary
The court considered several factors relevant to the exercise of discretion in granting leave to amend pleadings. Firstly, the court noted that the "forensic landscape" in this case did not change with the decision in Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2018] FCA 1556; 136 IPR 8, as Otsuka/BMS were already aware from the outset of the proceedings that Generic Health's claim was, in part, a loss of opportunity case. The court emphasised that the particulars provided by Generic Health in the appendix to its Statements of Particulars of Claim for Damages made it clear that Otsuka/BMS had admitted to unqualified facts, not merely the existence of opportunities. Furthermore, the court found that the potential delay and additional evidence required by Generic Health to counter the admissions did not outweigh the need for the court to ensure that the proceedings were justly decided.
In light of the above considerations, the court granted leave to Otsuka/BMS to withdraw the specified admissions and file an amended Response to Statement of Particulars of Claim for Damages. The orders of the court included granting leave for the amendments sought, with Otsuka/BMS to pay Generic Health's costs incurred due to the amendments and the costs of the application to amend.
Orders
Orders of the court
1. Leave be granted to Otsuka/BMS to withdraw paras 30, 31, 32 and 33(a) of the Response to Statement of Particulars of Claim for Damages filed in Generic Health’s enforcement proceedings, and to file an amended Response to Statement of Particulars of Claim for Damages in the form annexed to their amended interlocutory application dated 17 September 2019.
2. Otsuka/BMS pay Generic Health’s costs thrown away by reason of the amendments sought.
3. Otsuka/BMS pay the costs of the application to amend.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Generic Health submits further that a withdrawal of the admissions now will occasion delay in the proceedings. It submits that it will be necessary for it to adduce evidence in support of the facts that would be in issue. It submits that it is no answer to say that it has already filed affidavit evidence that bears upon those facts when a withdrawal of the admissions will require it to adduce sufficiently detailed evidence of the relevant facts. CONSIDERATION I do not accept that the “forensic landscape” in this case changed with the decision in Sigma v Wyeth, in the sense that, for the first time, Otsuka/BMS were met with an unforeseen and new legal development, or were otherwise alerted to the fact that they had to meet a case for damages assessed on a loss of opportunity basis. From its inception, Generic Health’s claim against Otsuka/BMS has been particularised as, in part, a loss of opportunity case. The appendix to Generic Health’s Statements of Particulars of Claim for Damages provides the following particulars: 1.Loss of the opportunity:(a) to be the first entrant into the market in Australia for generic products containing aripiprazole by selling its GH Products from 1 April 2012;(b) to have the GH PBS Products listed on the Schedule of Pharmaceutical Benefits pursuant to the Pharmaceutical Benefits Scheme (“PBS”), from 1 April 2012;(c) to be the first generic pharmaceutical company to sell generic products containing aripiprazole in the PBS market by selling the GH PBS Products in Australia from 1 April 2012;(d) to sell the GH Products during a period when sales of Respondents’ Registered Aripiprazole Products were higher in volume than on and from 1 December 2016;(e) to penetrate the market for other generic products and to sell additional products; (f) to sell to new customers (such as pharmacies or pharmacy buying groups); and(g) to strengthen relationships with existing customers. These particulars could not have escaped Otsuka/BMS’s attention. Although sub-paras 1(b) and (c) of the appendix refer to the “loss of opportunity” to obtain PBS listing, and the “loss of opportunity” to sell the GH products on the PBS market from 1 April 2012, paras 30 and 31(a) of the Statement of Particulars of Claim for Damages filed in the primary proceeding, and paras 32 and 33(a) of the Statement of Particulars of Claim for Damages filed in the appeal proceeding, plead unconditional “facts”, not simply “opportunities”. Despite a submission by Otsuka/BMS in oral argument to the contrary, I do not think that these allegations take their colour from sub-paras 1(b) and (c) of the appendix, such that Otsuka/BMS should be taken as having admitted no more than the existence of opportunities, as opposed to facts simpliciter. If opportunities alone have been admitted, it is difficult to understand why the present applications to withdraw the admissions have been made. Indeed, the correspondence to which I have referred makes it abundantly clear that Otsuka/BMS understood that they had admitted unqualified facts, not simply the existence of opportunities.